LeMaitre Vascular, Inc. $LMAT Shares Sold by Driehaus Capital Management LLC

Key Points

• Driehaus Capital Management has decreased its stake in LeMaitre Vascular by 41.5%, selling 109,214 shares, and now holds approximately 0.68% of the company valued at $12.9 million.
• CEO George W. Lemaitre sold 100,000 shares for over $9.35 million, reducing his ownership by 5.47% to 1.73 million shares, valued at approximately $161.5 million.
• The company reported a 15% increase in revenue year-over-year with earnings per share of $0.60, surpassing analyst expectations of $0.57 per share.

Driehaus Capital Management LLC cut its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 41.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 154,006 shares of the medical instruments supplier's stock after selling 109,214 shares during the quarter. Driehaus Capital Management LLC owned 0.68% of LeMaitre Vascular worth $12,921,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Opal Wealth Advisors LLC purchased a new position in LeMaitre Vascular during the first quarter worth approximately $26,000. NBC Securities Inc. acquired a new stake in LeMaitre Vascular in the 1st quarter worth $36,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in LeMaitre Vascular in the first quarter valued at about $50,000. US Bancorp DE raised its stake in shares of LeMaitre Vascular by 36.0% during the first quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier's stock worth $117,000 after buying an additional 368 shares during the last quarter. Finally, Cetera Investment Advisers increased its stake in LeMaitre Vascular by 11.5% in the fourth quarter. Cetera Investment Advisers now owns 2,753 shares of the medical instruments supplier's stock valued at $254,000 after purchasing an additional 284 shares in the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Bridget A. Ross sold 2,500 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $94.00, for a total transaction of $235,000.00. Following the transaction, the director owned 2,916 shares of the company's stock, valued at approximately $274,104. This represents a 46.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David B. Roberts sold 10,815 shares of LeMaitre Vascular stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $92.39, for a total value of $999,197.85. Following the sale, the director directly owned 17,976 shares of the company's stock, valued at $1,660,802.64. This trade represents a 37.56% decrease in their position. The disclosure for this sale can be found here. Insiders sold 120,815 shares of company stock valued at $11,280,206 over the last ninety days. 9.50% of the stock is owned by corporate insiders.

LeMaitre Vascular Price Performance

Shares of LMAT stock traded up $0.76 during trading hours on Friday, hitting $97.83. 31,389 shares of the company's stock were exchanged, compared to its average volume of 189,420. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. LeMaitre Vascular, Inc. has a 12-month low of $71.42 and a 12-month high of $109.58. The company has a market capitalization of $2.21 billion, a PE ratio of 47.49, a PEG ratio of 2.43 and a beta of 0.79. The business's 50 day simple moving average is $88.34 and its 200-day simple moving average is $86.34.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The company had revenue of $63.15 million for the quarter, compared to analysts' expectations of $62.48 million. During the same quarter in the previous year, the business posted $0.52 EPS. LeMaitre Vascular's revenue was up 15.0% compared to the same quarter last year. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. On average, equities research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 4th. Investors of record on Thursday, August 21st were paid a dividend of $0.20 per share. The ex-dividend date of this dividend was Thursday, August 21st. This represents a $0.80 dividend on an annualized basis and a yield of 0.8%. LeMaitre Vascular's dividend payout ratio is presently 38.83%.

Analysts Set New Price Targets

A number of brokerages have commented on LMAT. Barrington Research upgraded shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price target for the company in a research note on Wednesday, August 6th. Cantor Fitzgerald lifted their price objective on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $97.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.